Which statement best describes the action of ipratropium in COPD management?

• A. It primarily decreases mucus production through cholinergic pathways.
• B. It acts as a beta-agonist to produce bronchodilation.
• C. It causes bronchodilation by blocking muscarinic receptors and reducing secretions.
• D. It inhibits prostaglandin synthesis to reduce inflammation.

Answer: (C)

Ipra­tropium is an inhaled anticholinergic medication that blocks muscarinic receptors in the airways. By inhibiting acetylcholine’s action on these receptors, the parasympathetic influence that causes bronchoconstriction is reduced, leading to bronchodilation. It also lessens glandular secretions in the airway, helping to decrease mucus burden.

This mechanism is distinct from beta-adrenergic agonists, which relax airway smooth muscle by stimulating beta-2 receptors. It’s also not about inhibiting prostaglandin synthesis. The best description is as a muscarinic blocker that produces bronchodilation and reduces secretions, which aligns with ipratropium’s role in COPD management.